ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.
A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
Investor's Business Daily on MSN2h
AstraZeneca Dips As Drug Smuggling Allegations Undo Third-Quarter Beat And RaiseAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock reversed an earlier dip amid the ongoing criminal probe in China.Please watch the video at Investors.
AstraZeneca and Daiichi Sankyo withdrew their filing for datopotamab deruxtecan (Dato-DXd) in nonsquamous non-small cell lung ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...
Tagrisso sales were up 14% to $1.67 billion (17% at CER), Calquence sales increased 24% (25% at CER) to $8.13 million, and ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback